Cover Image
市場調查報告書

有機磷及氨基甲酸酯中毒 - 開發中產品分析

Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 357980
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
有機磷及氨基甲酸酯中毒 - 開發中產品分析 Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 39 Pages
簡介

本報告提供有機磷及氨基甲酸酯中毒治療藥的開發情形相關調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

有機磷及氨基甲酸酯中毒概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

有機磷及氨基甲酸酯中毒:企業開發中的治療藥

有機磷及氨基甲酸酯中毒:大學/機關研究中的治療藥

有機磷及氨基甲酸酯中毒:開發中產品概況

  • 初期階段的產品

有機磷及氨基甲酸酯中毒:企業開發中的產品

有機磷及氨基甲酸酯中毒:大學/機關研究中的產品

有機磷及氨基甲酸酯中毒的治療藥開發作的企業

  • Countervail Corporation
  • Hager Biosciences, LLC

有機磷及氨基甲酸酯中毒:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

有機磷及氨基甲酸酯中毒:開發中止的產品

有機磷及氨基甲酸酯中毒:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8566IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 2 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively for Organophosphate and Carbamate Poisoning.

Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Organophosphate and Carbamate Poisoning Overview
  • Therapeutics Development
    • Pipeline Products for Organophosphate and Carbamate Poisoning - Overview
    • Pipeline Products for Organophosphate and Carbamate Poisoning - Comparative Analysis
  • Organophosphate and Carbamate Poisoning - Therapeutics under Development by Companies
  • Organophosphate and Carbamate Poisoning - Therapeutics under Investigation by Universities/Institutes
  • Organophosphate and Carbamate Poisoning - Pipeline Products Glance
    • Early Stage Products
  • Organophosphate and Carbamate Poisoning - Products under Development by Companies
  • Organophosphate and Carbamate Poisoning - Products under Investigation by Universities/Institutes
  • Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
    • Countervail Corporation
    • Hager Biosciences, LLC
  • Organophosphate and Carbamate Poisoning - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AM-132 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galantamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PlantVax-1502-H-N - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RS-194B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate BuChE for Carbamate and Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Organophosphate and Carbamate Poisoning - Discontinued Products
  • Organophosphate and Carbamate Poisoning - Product Development Milestones
    • Featured News & Press Releases
      • Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Organophosphate and Carbamate Poisoning, H2 2016
  • Number of Products under Development for Organophosphate and Carbamate Poisoning - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corporation, H2 2016
  • Organophosphate and Carbamate Poisoning - Pipeline by Hager Biosciences, LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Organophosphate and Carbamate Poisoning - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Organophosphate and Carbamate Poisoning, H2 2016
  • Number of Products under Development for Organophosphate and Carbamate Poisoning - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Action, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top